Join to View Full Profile
4420 Lake Boone TrlSuite 200Raleigh, NC 27607
Phone+1 919-784-6818
Fax+1 919-784-6826
Dr. Speca is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified medical oncologist
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
University of MarylandResidency, Internal Medicine, 2001 - 2004
University of Vermont College of MedicineClass of 2001
Certifications & Licensure
NC State Medical License 2004 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Dec 10
Publications & Presentations
PubMed
- 5 citationsAssociation of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer.K A Nyrop, A Page, A M Deal, C Wagoner, E A Kelly
Supportive Care in Cancer. 2023-12-28 - 6 citationsBody mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.Kirsten A Nyrop, Jane Monaco, Sanah Vohra, Allison M Deal, William A Wood
Supportive Care in Cancer. 2023-03-02 - 12 citationsA biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer.Natalia Mitin, Kirsten A Nyrop, Susan L Strum, Anne Knecht, Lisa A Carey
NPJ Breast Cancer. 2022-09-08
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
